Antimyeloperoxidase (MPO) Antibodies

Overview:

For diagnosis and monitoring inflammatory activity in primary systemic small vessel vasculitides. The anti-MPO-ANCA EIA is useful for confirming positive ANCA results by IFA, particularly with the pANCA pattern. Presence of anti-MPO antibodies is highly specific for idiopathic and vasculitis-associated crescentic glomerulonephritis, classic polyarteritis nodosa, Churg-Strauss syndrome, and polyangiitis overlap syndrome without renal involvement. Levels of anti-MPO are elevated during active phases of disease and lower during remission. Therefore, monitoring anti-MPO levels can aid in disease management.

Results of this assay are not diagnostic proof of the presence or absence of disease and should be used in conjunction with clinical findings and other serological tests.

De'Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD. Relationship between disease activity and antineutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis. 1995 Mar; 25(3):380-389. PubMed 7872315

Gross WL, Csernok E. Immunodiagnostic and pathophysiologic aspects of antineutrophil cytoplasmic antibodies in vasculitis. Curr Opin Rheumatol. 1995 Jan; 7(1):11-19 (review). PubMed 7718417

Jennette JC, Falk RJ. Antineutrophil cytoplasmic antibodies: Discovery, specificity, disease associations and pathogenic potential. Adv Pathol Lab Med. 1995; 8:363-378.

Savige J, Gillis D, Benson E, et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol. 1999 Apr; 111(4):507-513. PubMed 10191771